773.282.9845
3401 N. Central Avenue Chicago, IL 60634

DEPRESSION AND INSOMNIA STUDY

DEPRESSION AND INSOMNIA

RESEARCH STUDY

What this study is investigating:

The purpose of this study is to compare the antidepressant effects of Seltorexant to Quetiapine extended release (XR) as an add-on treatment to your current antidepressant regimen for patients with major depressive disorder with sleep problems (such as difficulty falling asleep, staying asleep or poor sleep).

What are the medications being use? Quetiapine XR is FDA-approved to be used in conjunction with a traditional antidepressant to treat depressive symptoms that are not adequately treated by an antidepressant medication on its own. Quetiapine XR is sometimes prescribed off-label as a short-term sleep aid. Seltorexant is an investigational product that is being researched to measure its efficacy in treating symptoms of both depression and insomnia.

Overview: This is a 27–32-week long study that entail weekly to bi-weekly in-office visits. Some visits may be done remotely.

You May Qualify If:
–        You are 18 to 65 years of age
–        You have started an oral antidepressant within the past year and are still experiencing symptoms of depression
–        Please Note: You will be required to show verification of your current antidepressant start date

Qualified candidates will be compensated $75 for each in-office visit. Free transportation assistance may be provided to those who enroll.

Contact Us